CA3141712A1 - Gene therapy for alzheimer's disease - Google Patents
Gene therapy for alzheimer's disease Download PDFInfo
- Publication number
- CA3141712A1 CA3141712A1 CA3141712A CA3141712A CA3141712A1 CA 3141712 A1 CA3141712 A1 CA 3141712A1 CA 3141712 A CA3141712 A CA 3141712A CA 3141712 A CA3141712 A CA 3141712A CA 3141712 A1 CA3141712 A1 CA 3141712A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- composition
- psen1
- alzheimer
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852716P | 2019-05-24 | 2019-05-24 | |
| US62/852,716 | 2019-05-24 | ||
| PCT/US2020/034040 WO2020242892A1 (en) | 2019-05-24 | 2020-05-21 | Gene therapy for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3141712A1 true CA3141712A1 (en) | 2020-12-03 |
Family
ID=73553511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3141712A Pending CA3141712A1 (en) | 2019-05-24 | 2020-05-21 | Gene therapy for alzheimer's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12540334B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3976637A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7686573B6 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114144425B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020285638A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141712A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288266A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020242892A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019272848A1 (en) | 2018-05-22 | 2020-12-03 | The Brigham And Women's Hospital, Inc. | Gene therapy for alzheimer's disease |
| AU2020393917A1 (en) | 2019-11-29 | 2022-06-23 | Paros Bio, Inc. | Gene therapy for neurodegenerative disorders |
| JP7849078B2 (ja) * | 2022-01-29 | 2026-04-21 | シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド | Tpkを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用 |
| JP2025527208A (ja) * | 2022-07-25 | 2025-08-20 | ヴィコ・セラピューティクス・ベー・フェー | Appの異常なプロセシングに関連する疾患又は病態の治療用アンチセンスオリゴヌクレオチド |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| JPH10501686A (ja) | 1994-04-13 | 1998-02-17 | ザ ロックフェラー ユニヴァーシティ | 神経系の細胞へのdnaのaav仲介送達 |
| US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
| WO1997027296A1 (en) | 1996-01-26 | 1997-07-31 | Hsc Research And Development Limited Partnership | Nucleic acids and proteins related to alzheimer's disease, and uses therefor |
| AR020107A1 (es) | 1998-07-09 | 2002-04-10 | Boehringer Ingelheim Pharma | Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que |
| JP2002520055A (ja) | 1998-07-16 | 2002-07-09 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトプレセニリン関連タンパク質 |
| US6979537B2 (en) | 2000-01-10 | 2005-12-27 | Scios, Inc. | Methods for identifying inhibitors of neuronal degeneration |
| US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| US7271313B2 (en) | 2003-04-09 | 2007-09-18 | The Brigham And Women's Hospital, Inc. | Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss |
| CA2528963A1 (en) | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| WO2005037226A2 (en) | 2003-10-17 | 2005-04-28 | Georgia Tech Research Corporation | Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders |
| CA2541523A1 (en) | 2003-10-21 | 2005-05-06 | Applied Research Systems Ars Holding N.V. | Minimal dna sequence acting as a chromatin insulator and its use in protein expression |
| WO2005096781A2 (en) | 2004-04-06 | 2005-10-20 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using rna interference |
| CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| CN101031658A (zh) | 2004-05-26 | 2007-09-05 | 罗塞塔金诺米克斯有限公司 | 病毒和病毒相关mirna及其用途 |
| US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| WO2009042727A1 (en) | 2007-09-24 | 2009-04-02 | The Johns Hopkins University | Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin |
| AU2010316982B2 (en) | 2009-11-09 | 2013-09-12 | Genepod Therapeutics Ab | Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| CN103816540B (zh) | 2012-11-16 | 2018-01-02 | 中国科学院上海生命科学研究院 | 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用 |
| JP2016523835A (ja) | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
| WO2015006743A1 (en) | 2013-07-12 | 2015-01-15 | The Children's Hospital Of Philadelphia | Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies |
| GB201404470D0 (en) | 2014-03-13 | 2014-04-30 | Ucl Business Plc | Therapeutic methods and materials |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| US10350245B2 (en) * | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| EP3270960A4 (en) | 2015-03-20 | 2018-08-08 | Bluebird Bio, Inc. | Vector formulations |
| US10568516B2 (en) | 2015-06-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| CA3025626A1 (en) | 2016-05-27 | 2017-11-30 | Transcriptx, Inc. | Treatment of primary ciliary dyskinesia with synthetic messenger rna |
| WO2018045022A1 (en) | 2016-08-30 | 2018-03-08 | University Of South Florida | Adipose derived stem cell exosomes and uses thereof |
| WO2018140532A1 (en) | 2017-01-24 | 2018-08-02 | Fred Hutchinson Cancer Research Center | Systems and methods for hematopoietic cell expansion utilizing hydrogels |
| US11713470B2 (en) | 2017-03-20 | 2023-08-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted gene therapies for pain and other neuro-related disorders |
| US11015204B2 (en) * | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
| US11512327B2 (en) * | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| AU2019272848A1 (en) | 2018-05-22 | 2020-12-03 | The Brigham And Women's Hospital, Inc. | Gene therapy for alzheimer's disease |
| AU2020393917A1 (en) | 2019-11-29 | 2022-06-23 | Paros Bio, Inc. | Gene therapy for neurodegenerative disorders |
| EP4096786A4 (en) | 2020-01-31 | 2024-04-10 | Paros Bio, Inc. | GENE THERAPY FOR NEURODEGENERATIVE DISORDERS USING POLYNUCLEOTIDE SILENCING AND REPLACEMENT |
-
2020
- 2020-05-21 CA CA3141712A patent/CA3141712A1/en active Pending
- 2020-05-21 AU AU2020285638A patent/AU2020285638A1/en not_active Abandoned
- 2020-05-21 EP EP20813435.3A patent/EP3976637A4/en active Pending
- 2020-05-21 CN CN202080052274.9A patent/CN114144425B/zh active Active
- 2020-05-21 US US17/613,612 patent/US12540334B2/en active Active
- 2020-05-21 WO PCT/US2020/034040 patent/WO2020242892A1/en not_active Ceased
- 2020-05-21 JP JP2021569550A patent/JP7686573B6/ja active Active
-
2021
- 2021-11-21 IL IL288266A patent/IL288266A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7686573B2 (ja) | 2025-06-02 |
| US12540334B2 (en) | 2026-02-03 |
| WO2020242892A1 (en) | 2020-12-03 |
| IL288266A (en) | 2022-01-01 |
| CN114144425A (zh) | 2022-03-04 |
| JP2022533451A (ja) | 2022-07-22 |
| US20220235374A1 (en) | 2022-07-28 |
| JP7686573B6 (ja) | 2025-07-04 |
| EP3976637A1 (en) | 2022-04-06 |
| CN114144425B (zh) | 2025-05-13 |
| EP3976637A4 (en) | 2023-07-12 |
| AU2020285638A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497608B2 (en) | Gene therapy for Alzheimer's disease | |
| US12201658B2 (en) | Viral gene therapy as treatment for cholesterol storage disease or disorder | |
| JP7436089B2 (ja) | 前頭側頭型認知症の治療 | |
| AU2015364636B9 (en) | Gene therapy for Juvenile Batten Disease | |
| US12540334B2 (en) | Gene therapy for Alzheimer's disease | |
| JP7860958B2 (ja) | メチルcpg結合タンパク質2(mecp2)プロモータ配列を含む核酸構築体を用いた遺伝子治療 | |
| CN113557243A (zh) | 用于神经变性疾病的基因疗法 | |
| AU2020391518A1 (en) | APOE gene therapy | |
| US20240327477A1 (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| CN114127296A (zh) | Ube3a基因和表达盒及其应用 | |
| US20230242602A1 (en) | Zinc finger protein transcription factors for repressing tau expression | |
| CA3159309A1 (en) | Gene therapy for neurodegenerative disorders | |
| CN116670291A (zh) | 用于神经退行性疾病的基因疗法 | |
| CA3140507A1 (en) | Insulin gene therapy | |
| JP2017123840A (ja) | グルコーストランスポーター1発現用アデノ随伴ウイルスベクター | |
| WO2024052413A1 (en) | Beta-hexosaminidase vectors | |
| US20250186621A1 (en) | Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom | |
| RU2828216C2 (ru) | Модуляторы экспрессии гена открытой рамки считывания 72 хромосомы 9 и их применения | |
| WO2024259064A1 (en) | Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom | |
| AU2023361030A1 (en) | Gene therapy treatment | |
| CN121263062A (zh) | 阿尔茨海默病淀粉样β斑块病变快速发作的动物模型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250516 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250516 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251008 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260727 |